Quick Answer
Protalix BioTherapeutics, Inc. reported Diluted EPS of $0.08 per share (loss) for fiscal year 2025.
Protalix BioTherapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.08 | -300.0% |
| 2024 | $0.04 | -55.6% |
| 2023 | $0.09 | +129.0% |
| 2022 | -$0.31 | +50.0% |
| 2021 | -$0.62 | -181.8% |
| 2020 | -$0.22 | +82.1% |
| 2019 | -$1.23 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.03 | +0.0% | — |
| June 30, 2025 | $0.00 | +100.0% | +100.0% |
| March 31, 2025 | -$0.05 | +16.7% | -266.7% |
| September 30, 2024 | $0.03 | +175.0% | +200.0% |
| June 30, 2024 | -$0.03 | -114.3% | +50.0% |
| March 31, 2024 | -$0.06 | -20.0% | -50.0% |
| September 30, 2023 | -$0.04 | +42.9% | -119.0% |
| June 30, 2023 | $0.21 | +290.9% | +520.0% |
- Protalix BioTherapeutics, Inc. showed a decrease of -300.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Protalix BioTherapeutics, Inc.’s diluted eps has grown by 93.5% (from $1.23 per share (loss) to $0.08 per share (loss)).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: